This site is intended for US healthcare professionals.
Fennec HEARS™ provides support to you, your patients, and their families
Discover the full suite of resources and services from Fennec HEARS™
Financial support for eligible patients
- If you have commercial or private health insurance, you may pay as little as a $0 copay
- Call 1-833-7PEDMARK (1-833-773-3627) to enroll in the program and receive a copay savings card
- If you have government insurance like Medicaid, copay assistance may be available through independent charities
- Call 1-833-7PEDMARK (1-833-773-3627) for assistance locating an organization
- If you are uninsured, the Fennec Patient Assistance Program may be able to help.
- Call 1-833-7PEDMARK (1-833-773-3627) for more information
Eligible patients may pay as little as
a $0 copay for PEDMARK
Patient support to help children getting started on PEDMARK
Once a healthcare professional has prescribed PEDMARK, Fennec HEARS™ can:
- Help answer questions regarding insurance coverage for PEDMARK
- Provide tips and resources for accessing treatment
A Fennec HEARS™ professional does not offer medical advice or replace discussions with a healthcare provider.
Contact Fennec HEARS™ at 1-833-7PEDMARK (1-833-773-3627) from 9 AM to 6 PM ET, Monday through Friday.
Fennec HEARS™ is not related to acquisition
purchasing and reimbursement.
Information on these areas is available here.
Talk to a Fennec representative for more information.
IMPORTANT SAFETY INFORMATION
- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
- Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
- PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.
- Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
- Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73 m2.
- Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.
- The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
Please see full Prescribing Information for PEDMARK.
INDICATIONS AND USAGE
PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non‑metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.